gpi16 Antibody

What is GPI16 and what role does it play in the GPI anchor biosynthesis pathway?

GPI16 is a crucial subunit of the glycosylphosphatidylinositol (GPI) transamidase complex, which functions as a transmembrane protein that adds GPI anchors to newly synthesized proteins. It serves as the human PIG-Tp homolog in yeast models . The GPI biosynthetic pathway involves more than 30 genes that collectively ensure the correct attachment of GPI anchors to proteins destined for the cell surface. GPI16 specifically participates in the final step of GPI-anchored protein biosynthesis, where the transamidase complex cleaves the C-terminal GPI signal sequence and attaches the GPI anchor to the newly formed C-terminus of the protein .

Methodologically, researchers investigating GPI16 function typically employ knockout or knockdown approaches to assess the consequences of GPI16 deficiency on:

• Surface expression of GPI-anchored proteins

• Sensitivity to phosphatidylinositol-specific phospholipase C

• Cellular recognition by GPI-binding toxins such as aerolysin

How do GPI16 antibodies differ from other antibodies targeting components of the GPI biosynthesis pathway?

GPI16 antibodies are specifically designed to recognize the GPI16 protein component of the transamidase complex, distinguishing it from antibodies that target other proteins in the GPI biosynthetic pathway such as PIGB, PIGO, PIGK, PGAP2, or PGAP5 . When selecting antibodies for GPI pathway research, it's important to note that:

• GPI16 antibodies typically recognize yeast Saccharomyces cerevisiae GPI16, as seen in product CSB-PA336505XA01SVG-10, which targets recombinant S. cerevisiae (strain ATCC 204508/S288c) GPI16 protein .

• In contrast, antibodies targeting the glucose-6-phosphate isomerase enzyme (also abbreviated as GPI) recognize a completely different protein involved in glycolysis and gluconeogenesis. These GPI antibodies are more commonly available for multiple species including human, mouse, and rat .

For accurate experimental design, researchers should verify the exact target and species reactivity of "GPI antibodies" to avoid confusion between GPI16 (the transamidase component) and GPI (the metabolic enzyme).

What are the most common applications for GPI16 antibodies in research?

GPI16 antibodies are valuable tools for multiple experimental approaches in GPI anchor biology:

Methodologically, researchers should:

• Always include appropriate positive controls (such as wild-type cells/tissue) and negative controls (such as GPI16 knockout cells) when establishing new applications

• Validate antibody specificity through knockout/knockdown experiments

• Consider cross-reactivity potential, especially when working with multiple species

How should I design experiments to study the functional impact of GPI16 using antibodies?

When designing experiments to investigate GPI16 function using antibodies, a multi-faceted approach is recommended:

• Knockout Validation: Generate GPI16 knockout cells using CRISPR/Cas9 to create negative controls for antibody validation and functional studies. The cell-based GPI knockout library approach described by researchers has proven effective for studying GPI biosynthesis genes .

• Co-localization Studies: Combine GPI16 antibodies with markers for the endoplasmic reticulum (where the GPI transamidase complex resides) to confirm subcellular localization.

• Phenotypic Analysis: After confirming GPI16 knockout/knockdown, analyze:

  • Surface expression of GPI-anchored proteins using flow cytometry

  • Sensitivity to PI-PLC (phosphatidylinositol-specific phospholipase C)

  • Aerolysin binding and toxicity profiles

• Co-immunoprecipitation: Use GPI16 antibodies to isolate the entire transamidase complex and identify interacting partners through mass spectrometry.

The experimental workflow should include appropriate controls:

• Wild-type cells as positive controls

• GPI16 knockout cells as negative controls

• Isotype-matched irrelevant antibodies as technical controls

What are the optimal conditions for using GPI16 antibodies in Western blotting applications?

For optimal Western blotting results with GPI16 antibodies, follow these methodological guidelines:

• Sample Preparation:

  • Extract proteins using buffers containing 1% Triton X-100 or similar detergents to solubilize membrane proteins effectively

  • Include protease inhibitors to prevent degradation of GPI16

• Gel Electrophoresis:

  • Use 4-12% gradient gels for optimal separation

  • Load 20-50 μg of total protein per lane

• Transfer and Blocking:

  • Transfer to PVDF membrane (preferred for hydrophobic proteins)

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Antibody Incubation:

  • Primary GPI16 antibody: 1:500-1:2000 dilution in blocking buffer, overnight at 4°C

  • Secondary antibody: HRP-conjugated anti-rabbit or anti-mouse (depending on primary antibody host), 1:5000 dilution for 1 hour at room temperature

• Detection:

  • Use enhanced chemiluminescence (ECL) detection systems

  • Expected molecular weight for yeast GPI16: approximately 50-60 kDa

For increased specificity, consider using recombinant GPI16 protein as a positive control and include a GPI16 knockout/knockdown sample as a negative control .

How can I validate the specificity of GPI16 antibodies in my experimental system?

Validating GPI16 antibody specificity requires a systematic approach:

• Genetic Validation:

  • Generate GPI16 knockout cells using CRISPR/Cas9 or siRNA knockdown

  • Compare antibody staining between wild-type and knockout/knockdown cells

  • Observe elimination or significant reduction of signal in knockout/knockdown cells

• Overexpression Validation:

  • Express tagged GPI16 (e.g., with FLAG or HA tag) in cells

  • Perform dual staining with anti-GPI16 and anti-tag antibodies

  • Confirm co-localization of signals

• Competitive Blocking:

  • Pre-incubate GPI16 antibody with recombinant GPI16 protein

  • Apply pre-absorbed antibody to samples

  • Confirm elimination of specific staining

• Cross-reactivity Testing:

  • Test antibody reactivity against lysates from multiple species if working in cross-species contexts

  • Confirm signal at the expected molecular weight (approximately 60 kDa for human GPI16)

• Mass Spectrometry Confirmation:

  • Perform immunoprecipitation with GPI16 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm presence of GPI16 and other known complex components

Document all validation results systematically, as this information is crucial for publication and reproducibility of findings .

How can GPI16 antibodies be used to investigate the relationship between GPI anchor biosynthesis and T cell exhaustion in cancer?

Recent research has revealed important connections between GPI anchor biosynthesis and T cell exhaustion in breast cancer. To investigate this relationship using GPI16 antibodies:

• Comparative Expression Analysis:

  • Use GPI16 antibodies along with other GPI biosynthesis markers (GPAA1, PIGU) in immunohistochemistry or immunofluorescence to analyze expression in tumor-infiltrating T cells versus peripheral T cells

  • Compare expression in exhausted (PD-1high, TIM-3high, LAG-3high) versus non-exhausted T cells

• Single-cell Analysis Pipeline:

  • Combine GPI16 antibody staining with T cell exhaustion markers in flow cytometry

  • Correlate GPI16 expression levels with exhaustion marker expression

  • Sort cells for downstream transcriptomic or functional analyses

• Functional Assessment:

  • Use GPI16 antibodies to track GPI anchor biosynthesis in T cells during activation, exhaustion, and potential rejuvenation

  • Monitor changes in GPI16 localization during T cell functional transitions

Research has shown that GPI anchor biosynthesis-related genes correlate with T cell exhaustion status and can predict prognosis in breast cancer patients. Similar to findings with other GPI anchor biosynthesis genes (GPAA1, PIGU), GPI16 expression patterns may provide insights into immune evasion mechanisms in the tumor microenvironment .

What approaches can I use to investigate the role of GPI16 in infectious disease models?

GPI16 and the GPI anchor biosynthesis pathway play significant roles in host-pathogen interactions, particularly in parasitic infections such as malaria. For investigating these interactions:

• Pathogen-Host Interface Studies:

  • Use GPI16 antibodies to track changes in host GPI biosynthesis machinery during infection

  • Compare GPI16 expression and localization between infected and uninfected cells

• Antibody Response Analysis:

  • Investigate whether patients develop antibodies against components of the GPI biosynthesis pathway, including GPI16

  • Correlate anti-GPI antibody levels with disease progression or resistance

• Therapeutic Target Assessment:

  • Use GPI16 antibodies to validate potential therapeutic interventions targeting the GPI biosynthesis pathway

  • Assess how modulation of GPI16 affects pathogen attachment or invasion

Evidence suggests that adults with resistance to clinical malaria contain high levels of persistent anti-GPI antibodies, whereas susceptible children lack or have low levels of short-lived antibody responses . The absence of persistent anti-GPI antibody responses correlates with malaria-specific anemia and fever, suggesting that anti-GPI antibodies may provide protection against clinical malaria . Investigating whether similar protective mechanisms involve recognition of GPI16 or modulation of its function could reveal new therapeutic approaches.

When using GPI16 antibodies, what are common pitfalls and how can they be addressed?

To address these challenges:

• Epitope Mapping: Determine which region of GPI16 your antibody recognizes, as accessibility may vary depending on protein conformation or complex formation

• Sample Preparation Optimization: For membrane proteins like GPI16, extraction conditions are critical; try different detergents (CHAPS, digitonin) to maintain native conformation

• Positive Controls: Include samples with confirmed GPI16 expression, such as specific yeast strains or transfected cell lines

• Cross-validation: Use multiple techniques (WB, IF, IHC) to confirm findings and multiple antibodies targeting different epitopes if available

How can I use GPI16 antibodies to investigate the structure and assembly of the GPI transamidase complex?

Investigating the structure and assembly of the GPI transamidase complex using GPI16 antibodies requires sophisticated biochemical approaches:

• Co-immunoprecipitation Strategy:

  • Use GPI16 antibodies immobilized on beads to pull down the entire transamidase complex

  • Analyze co-precipitated proteins (PIG-K/Gpi8, GAA1/GPAA1, PIG-S/Gpi17, PIG-T/Gpi16, and PIG-U/Gab1) by Western blotting or mass spectrometry

  • Compare complex composition under different cellular conditions

• Blue Native PAGE Analysis:

  • Extract membrane proteins under native conditions using mild detergents

  • Separate complexes by Blue Native PAGE

  • Detect GPI16 and associated proteins by Western blotting using specific antibodies

  • Identify different subcomplexes and intermediates

• Proximity Labeling:

  • Generate GPI16 fusion proteins with BioID or APEX2

  • Use GPI16 antibodies to confirm expression and localization

  • Identify proximal proteins through streptavidin pulldown and mass spectrometry

• Super-resolution Microscopy:

  • Use GPI16 antibodies in combination with antibodies against other complex components

  • Visualize co-localization at nanometer resolution

  • Track dynamic assembly/disassembly under different conditions

This approach has revealed that the GPI transamidase complex functions as an integrated unit, with GPI16 playing a structural role in complex stability. The cell-based GPI knockout library developed by researchers provides an excellent platform for these investigations .

How can GPI16 antibodies contribute to understanding GPI anchor diversity and its functional implications?

Recent research has revealed unexpected diversity in GPI anchor structures and their functional consequences. GPI16 antibodies can contribute to this emerging field in several ways:

• Substrate Specificity Investigation:

  • Use GPI16 antibodies to immunoprecipitate active transamidase complexes

  • Compare the substrate profiles of transamidase complexes from different cell types or under different conditions

  • Correlate GPI16 expression levels with GPI anchor structural diversity

• Tissue-Specific GPI Processing:

  • Apply GPI16 antibodies in tissue microarrays to map expression patterns across tissues

  • Correlate expression patterns with known tissue-specific GPI anchor structures

  • Investigate whether tissue-specific co-factors interact with GPI16 to modify transamidase activity

• Disease-Associated Variants:

  • Develop antibodies specific to disease-associated GPI16 variants

  • Compare processing efficiency and substrate specificity of normal versus variant GPI16

  • Investigate whether variants affect interaction with specific GPI precursors

This approach can help uncover how the transamidase complex, including GPI16, contributes to the structural diversity of GPI anchors observed across different cell types, with important implications for cell-specific functions and disease mechanisms .

What are the implications of combining GPI16 antibody studies with aerolysin binding profiles for understanding GPI anchor structure?

The combination of GPI16 antibody studies with aerolysin binding profiles provides powerful insights into GPI anchor structure and function:

• Structure-Function Correlation:

  • Use GPI16 antibodies to track GPI biosynthesis pathway activity

  • Correlate with aerolysin binding profiles to identify structural motifs recognized by the toxin

  • Map how different GPI16 expression levels affect aerolysin recognition patterns

• Diagnostic Applications:

  • Develop diagnostic approaches combining GPI16 antibody staining with aerolysin binding

  • Identify disease-specific patterns of GPI anchor modification

  • Create multiparameter flow cytometry panels for detecting abnormal GPI structures

• Therapeutic Development:

  • Use insights from combined GPI16/aerolysin studies to develop therapeutics targeting specific GPI structures

  • Validate target engagement using both GPI16 antibodies and aerolysin binding assays

Research has shown that while PGAP5-deficient cells express GPI-anchored proteins at levels comparable to wild-type cells, they show resistance to aerolysin, indicating that specific structural features of GPI anchors (such as EtNP on Man2) affect aerolysin binding . This combined approach can reveal how GPI16 and other transamidase components influence the final structure and recognition properties of GPI anchors.

How can GPI16 antibodies be used in developing new therapeutic approaches for GPI-related disorders?

GPI16 antibodies have potential applications in developing therapies for GPI-related disorders:

• Diagnostic Biomarker Development:

  • Use GPI16 antibodies alongside other GPI biosynthesis markers to develop diagnostic panels for GPI deficiency disorders

  • Create immunoassays for detecting abnormal GPI16 expression or localization in patient samples

  • Combine with functional assays (aerolysin sensitivity, PI-PLC treatment) for comprehensive diagnosis

• Therapeutic Target Validation:

  • Employ GPI16 antibodies to validate the effects of small molecule modulators of GPI biosynthesis

  • Monitor changes in GPI16 expression, localization, or complex formation during treatment

  • Correlate changes in GPI16 with functional outcomes in disease models

• Therapeutic Antibody Development:

  • Generate function-modulating antibodies targeting accessible epitopes of GPI16

  • Use existing GPI16 antibodies as research tools to identify potentially druggable sites

  • Develop antibody-drug conjugates targeting cells with aberrant GPI16 expression

Research has identified connections between GPI anchor biosynthesis and various diseases, including:

• T cell exhaustion in breast cancer

• Autoimmune conditions like rheumatoid arthritis

• Parasitic infections such as malaria

Understanding how GPI16 contributes to these conditions could lead to novel therapeutic approaches targeting specific aspects of GPI biosynthesis.

What resources are available for researchers working with GPI16 antibodies?

Researchers interested in GPI16 antibodies can access several valuable resources:

• Commercial Antibodies:

  • Cusabio offers customized GPI16 antibodies that react with Saccharomyces cerevisiae (strain ATCC 204508/S288c)

  • Various suppliers provide antibodies against other components of the GPI biosynthesis pathway

• Cell Line Resources:

  • A cell-based GPI knockout library including 32 genes involved in GPI biosynthesis in human embryonic kidney 293 cells

  • These cells provide valuable positive and negative controls for antibody validation

• Bioinformatics Tools:

  • BioGRID database for GPI16 interaction partners

  • KEGG database for GPI biosynthesis pathway mapping

  • UniProt resources for protein sequence information (UniProt ID: P38875 for yeast GPI16)

• Research Protocols:

  • Well-established protocols for studying GPI-anchored proteins include PI-PLC sensitivity assays, aerolysin binding assays, and surface biotinylation techniques

  • Methodologies for investigating GPI biosynthetic genes through knockout approaches are detailed in recent publications

These resources provide researchers with the tools needed to effectively investigate GPI16 function and its role in GPI anchor biosynthesis.

What are current knowledge gaps in our understanding of GPI16 function that future antibody-based research should address?

Despite significant advances, several critical knowledge gaps remain in our understanding of GPI16 function:

• Regulatory Mechanisms:

  • How is GPI16 expression regulated in different tissues and under different conditions?

  • Do post-translational modifications affect GPI16 function within the transamidase complex?

  • What signaling pathways modulate GPI16 activity in response to cellular stress?

• Species-Specific Differences:

  • How do the structure and function of GPI16 differ between species, particularly between yeast and mammals?

  • Are there species-specific interacting partners that modify GPI16 function?

  • How has GPI16 evolved across different organisms?

• Disease Associations:

  • How do mutations or expression changes in GPI16 contribute to human diseases?

  • Is GPI16 directly involved in the pathogenesis of GPI biosynthesis disorders?

  • Could GPI16 be a therapeutic target for conditions involving abnormal GPI anchoring?

• Structural Insights:

  • What is the three-dimensional structure of GPI16 within the transamidase complex?

  • How does GPI16 contribute to substrate recognition and catalysis?

  • What are the conformational changes in GPI16 during the transamidase reaction?